Nantkwest

Nantkwest company information, Employees & Contact Information

Explore related pages

Related company profiles:

NantKwest (NASDAQ: NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Company Details

Employees
38
Address
9920 Jefferson Blvd, Culver City,ca 90232,united States
Phone
(858)633-0300
Email
co****@****est.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Culver City, CA
Looking for a particular Nantkwest employee's phone or email?

Nantkwest Questions

News

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells - Frontiers

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells Frontiers

ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine - Business Wire

ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine Business Wire

2 Nants become one as Soon-Shiong combines NantKwest, ImmunityBio - Fierce Biotech

2 Nants become one as Soon-Shiong combines NantKwest, ImmunityBio Fierce Biotech

NantKwest and ImmunityBio work on Covid-19 vaccines and drugs - Pharmaceutical Technology

NantKwest and ImmunityBio work on Covid-19 vaccines and drugs Pharmaceutical Technology

NantKwest doses first patient in Merkel cell carcinoma therapy trial - Clinical Trials Arena

NantKwest doses first patient in Merkel cell carcinoma therapy trial Clinical Trials Arena

Soon-Shiong Steps Aside as CEO of NantKwest - Los Angeles Business Journal

Soon-Shiong Steps Aside as CEO of NantKwest Los Angeles Business Journal

NantKwest ‘Triangle-Offense’ Induces Immunogenic Cell Death - Vax-Before-Travel

NantKwest ‘Triangle-Offense’ Induces Immunogenic Cell Death Vax-Before-Travel

The ‘world’s richest doctor’ just got a very rich payout - statnews.com

The ‘world’s richest doctor’ just got a very rich payout statnews.com

Patrick Soon-Shiong Initiates Reverse Merger of NantKwest and ImmunityBio - BioSpace

Patrick Soon-Shiong Initiates Reverse Merger of NantKwest and ImmunityBio BioSpace

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment - BioInformant

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment BioInformant

Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion - Endpoints News

Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion Endpoints News

Biotech company launched by L.A. billionaire Soon-Shiong soars on Wall Street - Los Angeles Times

Biotech company launched by L.A. billionaire Soon-Shiong soars on Wall Street Los Angeles Times

NantKwest Gives Biotech Another Big IPO - The Wall Street Journal

NantKwest Gives Biotech Another Big IPO The Wall Street Journal

NantKwest’s billionaire CEO pocketed $148 million in total compensation last year - BioPharma Dive

NantKwest’s billionaire CEO pocketed $148 million in total compensation last year BioPharma Dive

This CEO's $148 Million in Pay May Rank Him No. 1 for 2015 - Bloomberg

This CEO's $148 Million in Pay May Rank Him No. 1 for 2015 Bloomberg

AIPLA: The Supreme Court Must Ensure the U.S. Government Adheres to the American Rule in Peter v. NantKwest - IPWatchdog.com

AIPLA: The Supreme Court Must Ensure the U.S. Government Adheres to the American Rule in Peter v. NantKwest IPWatchdog.com

This Doctor Was Likely America’s Best Paid CEO in 2015 - Fortune

This Doctor Was Likely America’s Best Paid CEO in 2015 Fortune

Immunotherapy for Dogs: Running Behind Humans - Frontiers

Immunotherapy for Dogs: Running Behind Humans Frontiers

Billionaire Soon-Shiong’s NantKwest surges 39% in first day of trading - Los Angeles Times

Billionaire Soon-Shiong’s NantKwest surges 39% in first day of trading Los Angeles Times

Soon-Shiong Names Adcock as CEO at NantKwest - Los Angeles Business Journal

Soon-Shiong Names Adcock as CEO at NantKwest Los Angeles Business Journal

Donald Trump considers NantKwest CEO for NIH chief - Fierce Biotech

Donald Trump considers NantKwest CEO for NIH chief Fierce Biotech

NantKwest (NK) Stock Price, News & Analysis - MarketBeat

NantKwest (NK) Stock Price, News & Analysis MarketBeat

NantKwest CEO (AKA World’s Richest Doctor) Rumored to Have Met Trump for Top NIH Job - BioSpace

NantKwest CEO (AKA World’s Richest Doctor) Rumored to Have Met Trump for Top NIH Job BioSpace

Biotechs See Boom And Bust In 2015 - Chemical & Engineering News

Biotechs See Boom And Bust In 2015 Chemical & Engineering News

Top Nantkwest Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant